TICKERNERD
Menu
CSTLCSTLHealthcare · Diagnostics & Research

CSTL Stock Forecast: Castle Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$33
+0.70% on the day

The 9 Wall Street analysts covering Castle Biosciences, Inc. hold a median 12-month price target of $45 — +35.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
92 / 100
Median analyst target
$45
Analysts covering
9
Revenue$103.5M+20.1% y/y
Operating income−$3.1M
Net income−$2.1M
Free cash flow$6.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
−1.0%
YTD
−14.9%
1Y
+48.1%
From 52W high
−23.1%
From 52W low
+82.4%
$18
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CSTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Castle Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Revisions
88
Volatility
84
Quality
79
Value
73
Accruals
72
Issuance
49
Size
44
Growth
40

Momentum (88): The shares have been drifting up relative to others.

Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CSTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CSTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26CSTLHigh $57Median $45Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $35Median $45High $57

The green dot is the last close — the median target sits +35.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026BTIGMaintainsBuy$40 → $44
25 June 2026Roth CapitalInitiatesBuy$40
25 June 2026Roth CapitalInitiatesBuy—
13 May 2026BTIGMaintainsBuy—
7 May 2026BairdMaintainsOutperform—
20 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026BairdMaintainsOutperform—
26 Jan 2026GuggenheimMaintainsBuy—
12 Jan 2026Lake StreetMaintainsBuy—
5 Jan 2026GuggenheimMaintainsBuy—
22 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025BTIGMaintainsBuy—
5 Nov 2025BTIGMaintainsBuy—
4 Nov 2025BairdMaintainsOutperform—
9 Sept 2025Canaccord GenuityMaintainsBuy—
21 May 2025ScotiabankMaintainsSector Outperform—
6 May 2025Canaccord GenuityMaintainsBuy—
6 May 2025Lake StreetMaintainsBuy—
28 Feb 2025BairdMaintainsOutperform—
2 Jan 2025Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSTL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CSTL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Castle Biosciences, Inc. returned +48.1% against +17.5% for the S&P 500, dividends included.

CSTL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26CSTLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CSTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Castle Biosciences, Inc. (CSTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.5×

Cheaper than 25% of US stocks

Price / sales
2.8×

Cheaper than 42% of US stocks

Price / book
2.1×

Cheaper than 41% of US stocks

EV / EBITDA
−47.3×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
20.1%

Higher than 69% of US stocks

Earnings growth (YoY)
20.1%

Higher than 58% of US stocks

Gross margin
77.1%

Higher than 89% of US stocks

Operating margin
−3.0%

Higher than 29% of US stocks

Net margin
−5.4%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−4.2%

Higher than 40% of US stocks

Return on assets
−1.4%

Higher than 39% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Castle Biosciences, Inc. (CSTL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Castle Biosciences, Inc. has a market value of $1.0B and an enterprise value of $781.3M.

  • Revenue in the twelve months to 30 June 2026: $357.3M. The latest quarter grew 20.1% year on year.

  • Net income over the same four quarters: −$19.4M, a −5.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.66.

  • Free cash flow in the twelve months to 30 June 2026: −$489K.

  • Shares outstanding: 30.5M.

  • Trailing P/E: 30.5×; forward P/E: −36.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Castle Biosciences, Inc. employs 1,002 people — $357K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

CSTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CSTLCastle Biosciences, Inc.$1.0B
92
OPKOPKO Health, Inc.$1.0B
76
FRNMFreenome, Inc.$1.3B
30
FLGTFulgent Genetics, Inc.$596.7M
51
PSNLPersonalis, Inc.$1.7B
43
WGSGeneDx Holdings Corp.$2.0B
46
NEONeoGenomics, Inc.$2.2B
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Castle Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CSTL news & analysis

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

PRNewsWire · 12 Oct 2026positive

Castle Biosciences announced that three studies of its TissueCypher Barrett’s Esophagus test—two case reports and one multicenter study—will be presented at the ACG 2026 meeting. The studies describe how the test may provide progression-risk information beyond histopathology to support surveillance and treatment decisions.

Why it matters — The presentation highlights clinical research on TissueCypher’s potential to inform risk-aligned management beyond biopsy findings alone.

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

PRNewsWire · 30 Sept 2026positive

Castle Biosciences announced it will present new DecisionDx-Melanoma data at the EADV Congress 2026, including late-breaking results showing low-risk patients had SLN positivity below 5% and eligible patients avoiding SLNB had 99.6% five-year recurrence-free survival. A separate ePoster showed the test identifies early-stage transected melanomas with recurrence risk similar to stage IIB disease.

Why it matters — These data support expanded clinical utility of DecisionDx-Melanoma in sentinel lymph node biopsy decision-making and risk-aligned post-surgical management, which could strengthen CSTL's product evidence.

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

PRNewsWire · 28 Sept 2026positive

Castle Biosciences announced the publication of a study showing its TissueCypher Barrett's Esophagus Test helped guide risk-aligned management decisions at an expert surgery center in 90% of patients with non-dysplastic Barrett's esophagus. The findings appeared in a published announcement from the company.

Why it matters — The study results provide clinical evidence supporting the utility of Castle's TissueCypher test in guiding management decisions for a common patient population, potentially supporting adoption and commercial momentum.

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

PRNewsWire · 24 Sept 2026positive

Castle Biosciences announced the publication of a new study on atopic dermatitis showing that more than half of patients using targeted systemic therapies modified their treatment due to lack of efficacy. The study also found that 94% of patients open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment.

Why it matters — The study highlights a clinical need for molecular guidance in atopic dermatitis treatment selection, reinforcing the potential value of Castle's AdvanceAD-Tx test.

Castle Biosciences to Open New Laboratory Facility in Scottsdale

PRNewsWire · 22 Sept 2026positive

Castle Biosciences announced the opening of a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona. The expansion is intended to support growing test volumes and the company's long-term growth in the region.

Why it matters — CSTL watchers would see the facility expansion as a sign of the company's capacity to handle increasing test demand and invest in its future operational growth.

FAQ

Frequently asked questions about CSTL stock

What is the CSTL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Castle Biosciences, Inc. have a median 12-month price target of $45, with estimates ranging from $35 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CSTL stock a buy right now?

Of the 9 analysts covering Castle Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Castle Biosciences, Inc. 92 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CSTL?

As at 14 Oct 2026, Castle Biosciences, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will CSTL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +35.9% from the last close, and Ticker Nerd's factor model ranks Castle Biosciences, Inc. 92 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CSTL stock forecast for 2030?

No analyst covering Castle Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $57 over the next 12 months.

How has CSTL stock performed over the past year?

Castle Biosciences, Inc. returned +48.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Castle Biosciences, Inc. do?

Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making.

What is the latest news on CSTL?

The most recent item we track (PRNewsWire, 12 Oct 2026): "ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus". Castle Biosciences announced that three studies of its TissueCypher Barrett’s Esophagus test—two case reports and one multicenter study—will be presented at the ACG 2026 meeting. The studies describe how the test may provide progression-risk information beyond histopathology to support surveillance and treatment decisions.

Company

About Castle Biosciences, Inc.

Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.

CEO Mr. Derek J. Maetzold · 1,002 employees · United States · https://castlebiosciences.com